In a clinical trial that analyzed toripalimab therapy (a PD-1 antibody) in advanced GC, patients with TMB-high had significant higher OS (14.6 months) than those with TMB-low (4.0 months) with patients.80 Patients with TMB-high versus TMB-low also had enhanced ORR (33.3% vs 7.1%), and a numerically longer PFS, but without statistical significance. This evidence concerns the gene PDCD1 and gastric cancer.